Drug discovery is the most expensive, time demanding and challenging project in biopharmaceutical companies which aims at the identification and optimization of lead compounds from large-sized chemical libraries. The lead compounds should have high affinity binding and specificity for a target associated with a disease and in addition they should have favorable pharmacodynamic and pharmacokinetic properties (grouped as ADMET properties). Overall, drug discovery is a multivariable optimization and can be carried out in supercomputers using a reliable scoring function which is a measure of binding affinity or inhibition potential of the drug-like compound. The major problem is that the number of compounds in the chemical spaces is huge making the computational drug discovery very demanding. However, it is cheaper and less time consuming when compared to experimental high throughput screening. As the problem is to find the most stable (global) minima for numerous protein-ligand complexes (at the order of 10$^6$ to 10$^{12}$), the parallel implementation of in-silico virtual screening can be exploited to make the drug discovery in affordable time. In this review, we discuss such implementations of parallelization algorithms in virtual screening programs. The nature of different scoring functions and search algorithms are discussed, together with a performance analysis of several docking softwares ported on high-performance computing architectures.
翻译:药物发现是生物制药公司中最昂贵、最需要时间和最具挑战性的项目,目的是从大型化学图书馆中查明和优化铅化合物,铅化合物对于与疾病有关的目标应具有高度的亲近性和特殊性,此外,铅化合物应具有有利的药用动力学和药用动力学特性(归为ADMET特性)。总体而言,药物发现是一种多变的优化,可以使用可靠的评分功能在超级计算机中进行,这是对类似药物化合物的约束性亲近性或抑制潜力的一种衡量。主要问题在于化学空间中的化合物数量巨大,使得计算药物发现要求很高。然而,与实验性高吞吐量筛选相比,其成本更低,耗时更少。由于问题在于要找到许多蛋白结和复杂的最稳定的(全球)迷你(约10-6美元至10美元),平行虚拟筛查的平行实施可以用来在可承受的时间里进行毒品发现。在本次审查中,我们讨论的是,在一系列平行分析中进行这种平行性分析时,我们共同讨论这种平行性分析的高级性质。